Objective Brain metastasis is frequently found in patient with advanced non-small cell lung
cancer. Gefitinib is a inhibitor of epidermal growth factor receptor and can be used for the …

吉非替尼是一种口服的表皮生长因子受体酪氨酸激酶抑制剂 (EGFR-TKI), 是治疗晚期非小细胞
肺癌 (NSCLC) 的有效靶向药物之一. 本研究的目的是探讨吉非替尼治疗 NSCLC …

Background: Brain metastases are a common occurrence in patients with non-small-cell
lung cancer (NSCLC). Whole-brain radiotherapy (WBRT) is the standard therapy; more …

Objective To evaluate the efficacies of gefitinib plus radiotherapy in the treatment of brain
metastases in non-small-cell lung carcinoma (NSCLC) patients. Methods A retrospective …

Gefitinib is active and well tolerated in patients with advanced non-small cell lung cancer
(NSCLC); however, its role in patients with brain metastases has not been clearly defined …

The clinical efficacy of gefitinib, a tyrosine kinase inhibitor of epidermal growth factor
receptor (EGFR), on brain metastases (BMs) from non–small-cell lung cancer (NSCLC) was …

Brain metastasis (BM) is common in patients with non‐small cell lung cancer (NSCLC).
Although epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have …

Gefitinib is the first inhibitor of the epidermal growth factor receptor that has shown activity in
non–small-cell lung cancer (NSCLC), but its potential value in the treatment of central …

BACKGROUND: Lung cancer is the leading cause of cancer deaths in most countries. In
patients with metastases, such as the brain, the 1-year survival is 10% and most of these …

Background Brain metastases (BM) are a common in patients with lung cancer. Although
whole-brain radiation therapy (WBRT) is the standard therapy, it may have a risk of decline …